A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

Neuralgia, Postherpetic Clinical Trial

Official title:

Proprietary Information - Exploratory (Non-confirmatory) Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00282763
• Other study ID #: 0686-005
• Secondary ID: 2005_090
• Status: Terminated
• Phase: Phase 2
• First received: January 24, 2006
• Last updated: November 20, 2015
• Start date: December 2005
• Est. completion date: August 2006

Study information

• Verified date: November 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this Study is to test the Safety and Effectiveness of MK0686 in relieving neuropathic (chronic) pain as experienced by patients with Postherpetic Neuralgia (Also Know as PHN or Post Shingles Pain).

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: August 2006
• Est. primary completion date: August 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Diagnosis of postherpetic neuralgia with pain having lasted at least 6 months

• Able to complete study questionnaires, patient diary, and comply with daily study medication

• Patient is not satisfied with current treatment for pain control

Exclusion Criteria:

• Pregnant or nursing female

• History of evidence of a condition that in the opinion of the investigator, may interfere with the study results (e.g., diabetic neuropathy of fibromyalgia) or pose undue risk to undergo the course of medication required by the study (e.g., unstable heart disease, morbid obesity, kidney or liver disease)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neuralgia
• Neuralgia, Postherpetic

Intervention

Drug:
• MK0686

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	proprietary information - exploratory (non-confirmatory) trial
Secondary	proprietary information - exploratory (non-confirmatory) trial